Evidence map›Paper›PMID 35356214›Full record

ReviewFrontiers in oncology2022

Liquid Biopsy and Artificial Intelligence as Tools to Detect Signatures of Colorectal Malignancies: A Modern Approach in Patient's Stratification.

Octav Ginghina, Ariana Hudita, Marius Zamfir, Andrada Spanu, Mara Mardare, Irina Bondoc, Laura Buburuzan, Sergiu Emil Georgescu, Marieta Costache, Carolina Negrei and 2 more

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Liquid biopsy in lung cancer.Breathe (Sheffield, England) · 2025
    Review
  17. Review
  18. Review
  19. Review
  20. Liquid Biopsy: The Challenges of a Revolutionary Approach in Oncology.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Octav GinghinaDepartment II, University of Medicine and Pharmacy "Carol Davila" Bucharest, Bucharest, Romania.
Ariana HuditaDepartment of Biochemistry and Molecular Biology, University of Bucharest, Bucharest, Romania.
Marius ZamfirDepartment of Surgery, "Sf. Ioan" Clinical Emergency Hospital, Bucharest, Romania.
Andrada SpanuDepartment of Surgery, "Sf. Ioan" Clinical Emergency Hospital, Bucharest, Romania.
Mara MardareDepartment of Surgery, "Sf. Ioan" Clinical Emergency Hospital, Bucharest, Romania.
Irina BondocDepartment of Surgery, "Sf. Ioan" Clinical Emergency Hospital, Bucharest, Romania.
Laura BuburuzanOncoTeam Diagnostic S.A., Bucharest, Romania.
Sergiu Emil GeorgescuDepartment of Biochemistry and Molecular Biology, University of Bucharest, Bucharest, Romania.
Marieta CostacheDepartment of Biochemistry and Molecular Biology, University of Bucharest, Bucharest, Romania.
Carolina NegreiDepartment of Toxicology, University of Medicine and Pharmacy "Carol Davila" Bucharest, Bucharest, Romania.
Cornelia NitipirDepartment II, University of Medicine and Pharmacy "Carol Davila" Bucharest, Bucharest, Romania.
Bianca GalateanuDepartment of Biochemistry and Molecular Biology, University of Bucharest, Bucharest, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is the second most frequently diagnosed type of cancer and a major worldwide public health concern. Despite the global efforts in the development of modern therapeutic strategies, CRC prognosis is strongly correlated with the stage of the disease at diagnosis. Early detection of CRC has a huge impact in decreasing mortality while pre-lesion detection significantly reduces the incidence of the pathology. Even though the management of CRC patients is based on robust diagnostic methods such as serum tumor markers analysis, colonoscopy, histopathological analysis of tumor tissue, and imaging methods (computer tomography or magnetic resonance), these strategies still have many limitations and do not fully satisfy clinical needs due to their lack of sensitivity and/or specificity. Therefore, improvements of the current practice would substantially impact the management of CRC patients. In this view, liquid biopsy is a promising approach that could help clinicians screen for disease, stratify patients to the best treatment, and monitor treatment response and resistance mechanisms in the tumor in a regular and minimally invasive manner. Liquid biopsies allow the detection and analysis of different tumor-derived circulating markers such as cell-free nucleic acids (cfNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs) in the bloodstream. The major advantage of this approach is its ability to trace and monitor the molecular profile of the patient's tumor and to predict personalized treatment in real-time. On the other hand, the prospective use of artificial intelligence (AI) in medicine holds great promise in oncology, for the diagnosis, treatment, and prognosis prediction of disease. AI has two main branches in the medical field: (i) a virtual branch that includes medical imaging, clinical assisted diagnosis, and treatment, as well as drug research, and (ii) a physical branch that includes surgical robots. This review summarizes findings relevant to liquid biopsy and AI in CRC for better management and stratification of CRC patients.

Indexed as

artificial intelligencecolorectal cancerliquid biopsypatients stratificationrobotic surgery

Identifiers

PMID35356214
PMCPMC8959149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.